Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
AMAG Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
AMAG Pharma Enters into Option Agreement to Acquire Rights of Orphan Drug Candidate from Velo Bio 14
Private Equity 15
GTCR Invests In Cord Blood Registry 15
MSMB Capital Management To Acquire AMAG Pharma 16
Partnerships 17
Cord Blood Registry Enters into Research Agreement with Cellular Dynamics 17
Licensing Agreements 18
AMAG Pharma and Endoceutics Pharma Enter into Licensing Agreement 18
AMAG Pharma Enters into Licensing Agreement with Palatin Tech 20
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 22
Equity Offering 24
AMAG Pharma Raises USD230.9 Million in Public Offering of Shares 24
AMAG Pharma Raises USD201 Million in Public Offering of Shares 26
Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To US$250 Million 28
Debt Offering 29
AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 29
AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 31
Amag Pharma Completes Public Offering Of Notes Due 2019 For US$200 Million 32
Asset Transactions 34
Amag Pharma Plans For Sale Of Drug Manufacturing Facility 34
Acquisition 35
AMAG Pharma Acquires Cord Blood Registry for USD700 Million 35
AMAG Pharma Acquires Lumara Health 37
AMAG Pharma Plans For Sale Of The Company 39
AMAG Pharmaceuticals Inc – Key Competitors 40
AMAG Pharmaceuticals Inc – Key Employees 41
AMAG Pharmaceuticals Inc – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 45
Financial Announcements 45
Nov 02, 2017: AMAG Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Highlights 45
Aug 03, 2017: AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update 48
May 02, 2017: AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update 52
Feb 14, 2017: AMAG Reports Fourth Quarter and Full Year 2016 Financial Results 54
Jan 09, 2017: AMAG Pharmaceuticals Provides Financial and Business Update 57
Nov 03, 2016: AMAG Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update 59
Aug 09, 2016: AMAG Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update 61
May 03, 2016: AMAG Pharmaceuticals Reports First Quarter 2016 Financial Results 64
Feb 17, 2016: AMAG Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results 66
Corporate Communications 68
Sep 29, 2017: AMAG Pharmaceuticals Appoints Tracy Palmer Berns as Chief Compliance Officer 68
Sep 07, 2017: AMAG Pharmaceuticals Appoints Laura Williams, M.D. as Senior Vice President of Clinical Development 69
Apr 25, 2017: AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance 70
Mar 06, 2017: AMAG Announces Management Changes and New Commercial Appointments 71
Dec 21, 2016: AMAG Pharmaceuticals Announces Appointment of Brian Kelley to Board of Directors 72
Apr 11, 2016: AMAG Pharmaceuticals Appoints Edward Myles as Chief Financial Officer 73
Jan 04, 2016: AMAG Pharmaceuticals Appoints Nicholas Grund as Chief Commercial Officer 74
Government and Public Interest 75
Dec 15, 2016: AMAG Pharmaceuticals Doubles Support of Prematurity Prevention Research 75
Product News 76
04/04/2016: AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection) 76
02/02/2017: AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration 77
Product Approvals 78
Jun 26, 2017: AMAG Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Makena (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector 78
Apr 17, 2017: AMAG Submits Supplemental New Drug Application to FDA for Makena (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use 79
Feb 23, 2016: AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection) 81
Clinical Trials 82
Oct 12, 2016: AMAG Pharmaceuticals Announces Achievement of Key Milestone in Next Generation Development Program for Makena 82
Other Significant Developments 83
Nov 08, 2017: AMAG Announces Autologous Cord Blood Cells Improve Motor Function in Some Children with Cerebral Palsy 83
Jul 15, 2016: PhRMA Welcomes Five New Member Companies 84
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
AMAG Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
AMAG Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
AMAG Pharma Enters into Option Agreement to Acquire Rights of Orphan Drug Candidate from Velo Bio 14
GTCR Invests In Cord Blood Registry 15
MSMB Capital Management To Acquire AMAG Pharma 16
Cord Blood Registry Enters into Research Agreement with Cellular Dynamics 17
AMAG Pharma and Endoceutics Pharma Enter into Licensing Agreement 18
AMAG Pharma Enters into Licensing Agreement with Palatin Tech 20
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 22
AMAG Pharma Raises USD230.9 Million in Public Offering of Shares 24
AMAG Pharma Raises USD201 Million in Public Offering of Shares 26
Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To US$250 Million 28
AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 29
AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 31
Amag Pharma Completes Public Offering Of Notes Due 2019 For US$200 Million 32
Amag Pharma Plans For Sale Of Drug Manufacturing Facility 34
AMAG Pharma Acquires Cord Blood Registry for USD700 Million 35
AMAG Pharma Acquires Lumara Health 37
AMAG Pharma Plans For Sale Of The Company 39
AMAG Pharmaceuticals Inc, Key Competitors 40
AMAG Pharmaceuticals Inc, Key Employees 41
AMAG Pharmaceuticals Inc, Other Locations 43
AMAG Pharmaceuticals Inc, Subsidiaries 43